(Q37733587)

22 August 2017

1 reference

title

An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders (English)

1 reference

22 August 2017

1 reference

Antoni Camins

1 reference

22 August 2017

Francesc Xavier Sureda

1 reference

22 August 2017

Felix Junyent

1 reference

22 August 2017

Ester Verdaguer

1 reference

22 August 2017

Jaume Folch

1 reference

22 August 2017

Carlos Beas-Zarate

1 reference

22 August 2017

Merce Pallas

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

587-604

1 reference

Promising strategies for the prevention of dementia

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Mechanisms of neuronal death in disease: defining the models and the players.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Apoptosis and human diseases: mitochondrion damage and lethal role of released cytochrome C as proapoptotic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Donepezil delays progression to AD in MCI subjects with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

ALS drug development: reflections from the past and a way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Current approaches in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Mitochondrial membrane permeabilization in neuronal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Mitochondrial membrane permeabilization in cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-beta and is overexpressed in dystrophic neurites in Alzheimer's brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Tipping the apoptotic balance in Alzheimer's disease: the abortosis concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Caspase activation in the limbic cortex of subjects with early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Role of huperzine a in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Lithium delays progression of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Leptin: a novel therapeutic strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Functional modulation of nuclear steroid receptors by tauroursodeoxycholic acid reduces amyloid beta-peptide-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Antioxidant therapy in Alzheimer's disease: theory and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Neuroprotective effects of Ginkgo biloba extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Effect of Ginkgo biloba (EGb 761) on staurosporine-induced neuronal death and caspase activity in cortical cultured neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Ginkgo biloba did not prevent dementia or Alzheimer disease in elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Ginkgo biloba for prevention of dementia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Long-term melatonin administration protects brain mitochondria from aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

The antiapoptotic activity of melatonin in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Reduced oxidative damage in ALS by high-dose enteral melatonin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Improved mitochondrial function and increased life span after chronic melatonin treatment in senescent prone mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Therapeutic potential of resveratrol: the in vivo evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Resveratrol improves health and survival of mice on a high-calorie diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Trans-resveratrol: a magical elixir of eternal youth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Resveratrol--a boon for treating Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Q10 therapy in patients with idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Assessment of coenzyme Q10 tolerability in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Coenzyme Q10 in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Adenosine A(2A) receptors in Parkinson's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Neuroprotection by tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Minocycline and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Revisiting safety of minocycline as neuroprotection in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

A role for mixed lineage kinases in granule cell apoptosis induced by cytoskeletal disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

Pharmacological treatment in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003781898

10.1517/13543781003781898

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference